MAPT and Alzheimer disease: These conflicting findings on the effects of donepezil on tau pathology may be due to differences in AD mouse models (tau-overexpressing PS19 mice vs. APP/PS1 and APP/PS1/Tau Tg mice), donepezil administration methods/durations, and donepezil dosages.